TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency
A Case Series
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 17, 2022
- Accepted in final form October 17, 2022
- First Published March 20, 2023.
Author Disclosures
- Ariane Soldatos, MD, MPH,
- Camilo Toro, MD,
- Patrycja Hoffmann, MS, CRNP,
- Tina Romeo, RN, BSN,
- Natalie Deuitch, MS, CGC,
- Alessandra Brofferio, MD,
- Ivona Aksentijevich, MD,
- Daniel L. Kastner, MD, PhD and
- Amanda K. Ombrello, MD
- Ariane Soldatos, MD, MPH,
None
NONE
None
Pediatric Neurology, Editorial Board Member, 2022-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Supported by the intramural research program of the National Institute of Neurological Disorders and Stroke
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Camilo Toro, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I'm a full time employee of the NIH. This work was supported by funding from the NIH intramural program.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Patrycja Hoffmann, MS, CRNP,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tina Romeo, RN, BSN,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Natalie Deuitch, MS, CGC,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Alessandra Brofferio, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ivona Aksentijevich, MD,
None
NONE
None
I serve as the Associte Editor for the Frontiers in Immunology since 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health, USA
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel L. Kastner, MD, PhD and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My work is funded by the Intramural Research Program of the National Human Genome Research Institute, NIH, Bethesda, MD
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Amanda K. Ombrello, MD
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the National Institute of Neurological Disorders and Stroke (A.S.); National Human Genome Research Institute (C.T., P.H., T.R., N.D., I.A., D.L.K., A.K.O.); and National Heart (A.B.), Lung, and Blood Institute, Bethesda, MD.
- Correspondence
Dr. Soldatos ariane.soldatos{at}nih.gov
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.